JXJie Xue

Jie Xue

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jie Xue has a total of 26 co-authors. Here are the top co-authors by number of shared publications:

  • Bei Shao

    Department of Neurology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China

    1 shared publication
  • Bei Shao

    Department of Neurology, First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China

    1 shared publication
  • Dong Zhang

    Department of Neurology, Yangpu Hospital Tongji University School of Medicine, Shanghai, China

    1 shared publication
  • Jie Chen

    Department of Neurology First Affiliated Hospital of Wenzhou Medical University Wenzhou China

    1 shared publication
  • Jie Xue

    Department of Neurology, Zhongshan Hospital, Fudan University, Shanghai, China; Department of Neurology, Yangpu Hospital Tongji University School of Medicine, Shanghai, China

    1 shared publication
  • Kai Zhao

    Department of Neurology First Affiliated Hospital of Wenzhou Medical University Wenzhou China

    1 shared publication

Latest Publications

  • Predictors of Very Poor Outcome After Mechanical Thrombectomy in Older Patients with Acute Ischemic Stroke

    by Jie Xue, Xiao-Guang Zhang, Dong Zhang, Liang Hu, Xu-Shen Xu, You-Mei Li, Yun-Hua Yue


  • Open Access

    Role ofsLOX‐1 in intracranial artery stenosis and in predicting long‐term prognosis of acute ischemic stroke

    by Xian‐Mei Li, Ping‐Ping Jin, Jie Xue, Jie Chen, Qin‐Fen Chen, Xiao‐Qian Luan, Zeng‐Rui Zhang, Tie‐Er Yu, Zheng‐Yi Cai, Kai Zhao, et al.

    Objective: The role ofsLOX‐1 in acute ischemic stroke still remains unclear. This study aims to demonstrate the value ofsLOX‐1 in evaluating degrees of intracranial artery stenosis and to predict prognosis in stroke.Methods: Two hundred and seventy‐two patients were included in this study and basic data were collected within 72 hr on admission. We assessed the association betweensLOX‐1 levels and stroke conditions in one‐year duration. After adjusting for potential confounders, regression analyses were performed.Results: We found thatsLOX‐1 levels were increased significantly in severe patients compared to the mild stroke group (p = .011). After adjusting confounders,sLOX‐1 was associated with a poor functional outcome in patients with an adjustedORof 2. 946 (95%CI, 1.788–4.856,p < .001). There was also positive correlation betweensLOX‐1 levels and the degrees of intracranial artery stenosis in the different groups (p = .029).Conclusions: Our study demonstrated thatsLOX‐1 levels could be used to evaluate the severity of stroke and the degrees of intracranial artery stenosis. Furthermore,sLOX‐1 could be exploited to predict the long‐term functional outcome of stroke.


  • Open Access

    Left atrial size and risk of recurrent ischemic stroke in a Chinese population

    by Jie Xue, Yuanshao Lin, Wensi Huang, Xiaoli Chen, Qian Li, Zhengyi Cai, Wanli Zhang, Yuansheng Ye, Bei Shao

    Background: Although a number of studies have reported the role of an increased left atrial (LA) size on stroke, limited data are collected about the relationship between LA enlargement and recurrent ischemic stroke in the Chinese population. Our aim was to assess the association of LA size with the risk of stroke recurrence, particularly with recurrent cardioembolic or cryptogenic stroke in ischemic stroke patients.Methods: The study recruited 313 consecutive patients with acute first‐ever ischemic stroke. Echocardiographic LA diameter was measured and indexed by height and body surface area separately. The endpoint was recurrent ischemic stroke. Cox proportional hazard models were used to examine the association of LA size with total recurrent ischemic stroke and recurrent cardioembolic or cryptogenic stroke while adjusting for baseline demographics characteristics, clinical factors, echocardiographic left ventricular ejection fraction, and medication.Results: Over a median follow‐up period of 1.63 years, 47 recurrent ischemic strokes (21 were cardioembolic or cryptogenic) occurred. In a multivariate model adjusted for potential confounders, compared with the bottom tertiles of LA diameter indexed to height (LA diameter/H), the top tertile of LA diameter/H was significantly associated with the total recurrent ischemic stroke (adjusted HR 3.610, 95% CI 1.870–6.967, p < .001) and the composite of recurrent cardioembolic or cryptogenic stroke (adjusted HR 5.673, 95% CI 1.780–18.084, p = .003). Results were similar when LA diameter indexed to body surface area (LA diameter/BSA) was involved in the analysis.Conclusion: LA size is an independent predictor of total recurrent ischemic stroke and the composite of recurrent cardioembolic or cryptogenic stroke.


  • Open Access

    Osthole Regulates TGF-β1 and MMP-2/9 Expressions via Activation of PPARα/γ in Cultured Mouse Cardiac Fibroblasts Stimulated with Angiotensin II

    by Rong Chen, Jie Xue, Meilin Xie

    PURPOSE. Our previous studies have demonstrated that osthole, an active constituent isolated from the fruit of Cnidium monnieri (L.) Cusson, can prevent isoprenaline-induced myocardial fibrosis in mice, but the underlying mechanism is still unclear. METHODS. The mouse cardiac fibroblasts (CFs) stimulated with angiotensin II (Ang II) were cultured and treated with different concentrations of osthole. The mRNA expressions of peroxisome proliferator-activated receptor (PPAR) α/γ, transforming growth factor β1 (TGF-β1), and matrix metalloproteinase (MMP)-2/9 were detected by reverse transcription polymerase chain reaction method, and the protein expressions of nuclear factor-κB (NF-κB) and TGF-β1 were detected by Western blot method, respectively. RESULTS. Following treatment of cells with osthole at 2.5, 5, 10 and 20 μg/mL, the NF-κB and TGF-β1 expressions were dose-dependently decreased, while the expressions of PPARα/γ and MMP-2/9 were dose-dependently increased. After the cells were preincubated with PPARα antagonist (MK886) or/and PPARγ antagonist (GW9662), the inhibitions of osthole on the NF-κB and TGF-β1 expressions were decreased or completely halted and the increment of osthole on the MMP-2/9 expressions were also decreased or completely cancelled. CONCLUSION. Osthole could inhibit the NF-κB and TGF-β1 expressions by activation of PPARα/γ, and subsequently enhance the MMP-2/9 expressions in cultured CFs, and these effects of osthole may play the beneficial roles in the prevention and treatment of myocardial fibrosis. This article is open to POST-PUBLICATION REVIEW. Registered readers (see "For Readers") may comment by clicking on ABSTRACT on the issue's contents page.